BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin Y, Zhang Z, Wang S, Cai J, Guo J. Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders. Rev Endocr Metab Disord 2020;21:421-9. [DOI: 10.1007/s11154-020-09586-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang R, Wu E, Deng X. Potential of Lycium barbarum polysaccharide for the control of glucose and lipid metabolism disorders: a review. International Journal of Food Properties 2022;25:673-80. [DOI: 10.1080/10942912.2022.2057529] [Reference Citation Analysis]
2 Xiao QA, He Q, Zeng J, Xia X. GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease. Biomed Pharmacother 2021;146:112582. [PMID: 34959119 DOI: 10.1016/j.biopha.2021.112582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Reyes-Cuapio E, Coronado-Álvarez A, Quiroga C, Alcaraz-Silva J, Ruíz-Ruíz JC, Imperatori C, Murillo-Rodríguez E. Juvenile cannabidiol chronic treatments produce robust changes in metabolic markers in adult male Wistar rats. Eur J Pharmacol 2021;910:174463. [PMID: 34478689 DOI: 10.1016/j.ejphar.2021.174463] [Reference Citation Analysis]
4 Zhang M, Cui C, Lin Y, Cai J. Ameliorating effect on glycolipid metabolism and chemical profile of Millettia speciosa champ. extract. J Ethnopharmacol 2021;279:114360. [PMID: 34166739 DOI: 10.1016/j.jep.2021.114360] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Neagu M, Constantin C, Bardi G, Duraes L. Adverse outcome pathway in immunotoxicity of perfluoroalkyls. Current Opinion in Toxicology 2021;25:23-9. [DOI: 10.1016/j.cotox.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]